Allergy Asthma Clin Immunol:屋尘螨过敏性鼻炎的舌下免疫治疗药片研究

2019-05-21 AlexYang MedSci原创

最近,有研究人员进行了成本最小化分析来评估利用SQ 屋尘螨舌下免疫治疗(SQ HDM SLIT)来对HDM诱导的过敏性鼻炎进行治疗的经济影响,而在研究所在地区,屋尘螨舌下免疫治疗(HDM SCIT)已经是一个可以选择的疗法。CMA被认为是合适的并且是基于SQ HDM SLIT药片治疗与HDM SCIT具有相当的疗效。研究人员在评估模型中采用了社会视角,包括了药物的相关花费、健康医疗服务和产出损失。

最近,有研究人员进行了成本最小化分析(CMA)来评估利用SQ 屋尘螨舌下免疫治疗(SQ HDM SLIT)来对HDM诱导的过敏性鼻炎进行治疗的经济影响,而在研究所在地区,屋尘螨舌下免疫治疗(HDM SCIT)已经是一个可以选择的疗法。

CMA被认为是合适的并且是基于SQ HDM SLIT药片治疗与HDM SCIT具有相当的疗效。研究人员在评估模型中采用了社会视角,包括了药物的相关花费、健康医疗服务和产出损失。研究发现,3年的SQ HDM SLIT药片直接花费要比HDM SLIT更高,在安大略和魁北克省中分别为($4732.12和$4829.03 vs. $3434.51和$2987.74)。然而,当把间接花费添加到模型中后,可以在安大略和魁北克省中分别节省$1833.00和$769.03。另外,不同的HDM SCIT资源使用、折扣率、滴定和维护注射、护理时间和每小瓶注射次数的敏感性分析表明SQ HDM SLIT药片在所有的情况中均比HDM SCIT节省更多。

最后,研究人员指出,CMA表明了SQ HDM SLIT药片治疗要比HDM SCIT治疗花费更少。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977142, encodeId=2ba019e71425d, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 08 19:30:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047117, encodeId=4916204e117db, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jun 18 00:30:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711954, encodeId=98b01e1195488, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Apr 13 16:30:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329242, encodeId=4b8d13292425f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348588, encodeId=fb0c13485884a, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2019-12-08 skhzy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977142, encodeId=2ba019e71425d, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 08 19:30:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047117, encodeId=4916204e117db, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jun 18 00:30:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711954, encodeId=98b01e1195488, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Apr 13 16:30:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329242, encodeId=4b8d13292425f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348588, encodeId=fb0c13485884a, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977142, encodeId=2ba019e71425d, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 08 19:30:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047117, encodeId=4916204e117db, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jun 18 00:30:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711954, encodeId=98b01e1195488, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Apr 13 16:30:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329242, encodeId=4b8d13292425f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348588, encodeId=fb0c13485884a, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2020-04-13 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977142, encodeId=2ba019e71425d, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 08 19:30:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047117, encodeId=4916204e117db, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jun 18 00:30:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711954, encodeId=98b01e1195488, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Apr 13 16:30:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329242, encodeId=4b8d13292425f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348588, encodeId=fb0c13485884a, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2019-05-23 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977142, encodeId=2ba019e71425d, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 08 19:30:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047117, encodeId=4916204e117db, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jun 18 00:30:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711954, encodeId=98b01e1195488, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Apr 13 16:30:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329242, encodeId=4b8d13292425f, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348588, encodeId=fb0c13485884a, content=<a href='/topic/show?id=54c24e71237' target=_blank style='color:#2F92EE;'>#屋尘螨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47712, encryptionId=54c24e71237, topicName=屋尘螨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu May 23 05:30:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]

相关资讯

Pediatr Allergy Immunol:过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮

4-1BB (CD137)是诱导肿瘤坏死因子受体(TNFR)家族的成员之一,并在调节T细胞(Treg)中表达来调控Treg,从而控制过敏性炎症。Pam3CSK4是一种合成的TLR2配体,能够扩展CD8+ Treg的功能,并且是过敏原免疫治疗(IT)很有希望的辅助因子。最近,有研究人员调查了是否屋尘螨(Der p)IT和Pam3CSK4能够增强CD8+CD25+CD137+ Treg抑制功能从而来减

Asian Pac J Allergy Immunol:盐水洗鼻对儿童过敏性鼻炎和哮喘益处研究

哮喘和过敏性鼻炎(AR)是气道慢性炎症疾病并且相互影响着疾病的严重度。最近,有研究人员调查了是否生理盐水洗鼻(NSI)能够改善哮喘和过敏性鼻炎(AR)儿童的气道高反应性和临床参数。研究人员招募了20名AR和哮喘儿童,年龄在6-18岁。患者被随机分成了2组:洗鼻组(8名男孩和2名女孩)和对照组(8名男孩和2名女孩)。洗鼻组每天都进行NSI。所有的参与者接受了为期12周的孟鲁司特,左西替利嗪,吸入糖皮

Int Immunopharmacol:过敏性鼻炎中桔皮素能够促进T细胞分化

桔皮素具有广谱的抗炎症作用。最近,有研究人员评估了是否桔皮素在调控T调节细胞(Tregs)和减弱过敏性鼻炎(AR)中具有功能。研究发现,在AR组中,桔皮素和地塞米松(DXM)给药均能够减弱呼吸道炎症,减少血清OVA诱导的lgE的产生,但是只有桔皮素给药能够恢复细胞因子的平衡。在AR小鼠或者CD4+T细胞分化中,脾脏CD4+CD25+FOXP3+Treg细胞的丰度和FOXP3转录因子水平在桔皮素治疗

Drug Deliv Transl Res:包含壳聚糖基纳米颗粒负载热敏原位凝胶的马来酸氯苯那敏在过敏性鼻炎治疗中的研究

最近,有研究人员制造了一个包含马来酸氯苯那敏(CPM)纳米颗粒的热敏凝胶,进行鼻腔给药从而对过敏性鼻炎进行有效的治疗。研究人员利用沉淀法获得了壳聚糖基纳米颗粒,之后在基于波洛沙姆407和卡波934p的黏附性热可逆凝胶中加入研制的NPs。研制的配方用来评估颗粒的大小、PDI、包封百分比和累积药物渗透百分比。研究发现,NP3配方具有最优的最小颗粒(143.9nm)、最大的包封比例(80.10±0.41

Int J Environ Res Public Health:亚洲糖尿病患者中二肽酰肽酶-4抑制剂与过敏性鼻炎相关性分析

最近,有研究人员尝试评估了二肽酰肽酶-4抑制剂(DPP-4)与过敏性鼻炎在糖尿病患者中可能的相关性。研究人员的研究群体包括了2009年到2012年之间的2型糖尿病(ICD-9-CM 250)患者群体,并分为DPP-4使用者和非使用者。研究人员在多变量逻辑回归分析模型中评估了倾向性评分来对过敏性鼻炎(ICD-9-CM 477.9)进行分析。每个组中包括了6204名患者。研究发现,DDP-4抑制剂使用

Clin Exp Allergy:肿瘤坏死因子α和白介素-5能够抑制嗅觉再生

嗅觉障碍在过敏性鼻炎患者中是一种常见的情况。这种情况被认为是由于炎症引起的嗅觉粘膜结构性和功能性的变化产生的。然而,目前对过敏性鼻炎嗅觉功能障碍的病理学理解仍旧不清楚。最近,有研究人员在过敏性鼻炎中调查了嗅觉神经细胞损伤的原因。研究发现,嗅球细胞(OSCs)表达了神经干细胞的标记。为了调查神经分化,研究人员通过免疫细胞组化染色发现Tuji1、GFAP、O4和OSCs量均显著增加。在对照和过敏性鼻炎